
FDA withdraws approval of 3 PARP inhibitors to treat ovarian cancer
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,